These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20947638)

  • 1. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
    Fell MJ; Witkin JM; Falcone JF; Katner JS; Perry KW; Hart J; Rorick-Kehn L; Overshiner CD; Rasmussen K; Chaney SF; Benvenga MJ; Li X; Marlow DL; Thompson LK; Luecke SK; Wafford KA; Seidel WF; Edgar DM; Quets AT; Felder CC; Wang X; Heinz BA; Nikolayev A; Kuo MS; Mayhugh D; Khilevich A; Zhang D; Ebert PJ; Eckstein JA; Ackermann BL; Swanson SP; Catlow JT; Dean RA; Jackson K; Tauscher-Wisniewski S; Marek GJ; Schkeryantz JM; Svensson KA
    J Pharmacol Exp Ther; 2011 Jan; 336(1):165-77. PubMed ID: 20947638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of the neurophysiological profile of group II metabotropic glutamate receptor activators and diazepam: effects on hippocampal and cortical EEG patterns in rats.
    Siok CJ; Cogan SM; Shifflett LB; Doran AC; Kocsis B; Hajós M
    Neuropharmacology; 2012 Jan; 62(1):226-36. PubMed ID: 21791219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
    Bespalov AY; van Gaalen MM; Sukhotina IA; Wicke K; Mezler M; Schoemaker H; Gross G
    Eur J Pharmacol; 2008 Sep; 592(1-3):96-102. PubMed ID: 18634781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
    Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
    J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor.
    Hiyoshi T; Marumo T; Hikichi H; Tomishima Y; Urabe H; Tamita T; Iida I; Yasuhara A; Karasawa J; Chaki S
    J Pharmacol Exp Ther; 2014 Dec; 351(3):642-53. PubMed ID: 25277141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
    Gilmour G; Broad LM; Wafford KA; Britton T; Colvin EM; Fivush A; Gastambide F; Getman B; Heinz BA; McCarthy AP; Prieto L; Shanks E; Smith JW; Taboada L; Edgar DM; Tricklebank MD
    Neuropharmacology; 2013 Jan; 64():224-39. PubMed ID: 22884720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782.
    Lavreysen H; Langlois X; Ahnaou A; Drinkenburg W; te Riele P; Biesmans I; Van der Linden I; Peeters L; Megens A; Wintmolders C; Cid JM; Trabanco AA; Andrés JI; Dautzenberg FM; Lütjens R; Macdonald G; Atack JR
    J Pharmacol Exp Ther; 2013 Sep; 346(3):514-27. PubMed ID: 23766542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents.
    Hikichi H; Murai T; Okuda S; Maehara S; Satow A; Ise S; Nishino M; Suzuki G; Takehana H; Hata M; Ohta H
    Eur J Pharmacol; 2010 Aug; 639(1-3):106-14. PubMed ID: 20371227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.
    Homayoun H; Jackson ME; Moghaddam B
    J Neurophysiol; 2005 Apr; 93(4):1989-2001. PubMed ID: 15590730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic profiles of TASP0443294, a novel and orally active positive allosteric modulator of metabotropic glutamate 2 receptor.
    Hikichi H; Hiyoshi T; Marumo T; Tomishima Y; Kaku A; Iida I; Urabe H; Tamita T; Yasuhara A; Karasawa J; Chaki S
    J Pharmacol Sci; 2015 Mar; 127(3):352-61. PubMed ID: 25837934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
    Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
    Martin JR; Bös M; Jenck F; Moreau J; Mutel V; Sleight AJ; Wichmann J; Andrews JS; Berendsen HH; Broekkamp CL; Ruigt GS; Köhler C; Delft AM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):913-24. PubMed ID: 9694950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.
    Johnson MP; Baez M; Jagdmann GE; Britton TC; Large TH; Callagaro DO; Tizzano JP; Monn JA; Schoepp DD
    J Med Chem; 2003 Jul; 46(15):3189-92. PubMed ID: 12852748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
    Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
    J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
    Johnson MP; Barda D; Britton TC; Emkey R; Hornback WJ; Jagdmann GE; McKinzie DL; Nisenbaum ES; Tizzano JP; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):271-83. PubMed ID: 15717213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.
    Lindemann L; Porter RH; Scharf SH; Kuennecke B; Bruns A; von Kienlin M; Harrison AC; Paehler A; Funk C; Gloge A; Schneider M; Parrott NJ; Polonchuk L; Niederhauser U; Morairty SR; Kilduff TS; Vieira E; Kolczewski S; Wichmann J; Hartung T; Honer M; Borroni E; Moreau JL; Prinssen E; Spooren W; Wettstein JG; Jaeschke G
    J Pharmacol Exp Ther; 2015 Apr; 353(1):213-33. PubMed ID: 25665805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization.
    Kalinichev M; Rouillier M; Girard F; Royer-Urios I; Bournique B; Finn T; Charvin D; Campo B; Le Poul E; Mutel V; Poli S; Neale SA; Salt TE; Lütjens R
    J Pharmacol Exp Ther; 2013 Mar; 344(3):624-36. PubMed ID: 23257312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.